FACT SHEET

Winter 2022

Nasdaq: SNPX

Pioneers of Restorative Therapeutics

Synaptogenix is a clinical-stage biopharmaceutical company discovering restorative, novel therapeutics for patients with life-altering neurodegenerative diseases and developmental disorders. Synaptogenix is currently conducting a National Institutes of Health (NIH) sponsored Phase 2b clinical trial of its lead therapeutic candidate Bryostatin-1 in patients suffering from moderate to severe Alzheimer's disease (AD). In addition to AD, preclinical studies have demonstrated Bryostatin-1's regenerative mechanisms of action for the rare disease Fragile X syndrome, and the U.S. Food and Drug Administration has granted the drug Orphan Drug Designation for this indication. Other potential indications include multiple sclerosis (MS), stroke, traumatic brain injury, and autism spectrum disorders. Bryostatin has already undergone testing in more than 1,500 people in cancer studies, thus creating a large safety data base that will further inform clinical trial designs.

Key Investment Considerations

- Technology developed over a decade through funding of **$200M+** by Blanchette Rockefeller Neurosciences Institute and the National Institutes of Health (NIH).
- Successful translation of decades of pre-clinical work to the clinic; **Phase 2b clinical trial underway** for Bryostatin-1 as a treatment for Alzheimer's disease.
- Massive market opportunity in Alzheimer's disease treatment; according to the Alzheimer's Association, AD treatment and care cost the U.S. government over **$305 billion** in 2020[1].
- Potential as treatment for additional central nervous system disorders including **Fragile X syndrome**, **multiple sclerosis (MS)**, **autism**, **Parkinson's disease**, **traumatic brain injury**, and **stroke**.
- Clean capital structure and strong cash position of **$31M**; six years of operating runway.
- Leadership with deep expertise in neurodegenerative disorders and successful track records in both drug discovery and development; **30+ years** of experience with the development of bryostatin and other platform drugs.



Partnerships

Blanchette Rockefeller Neurosciences Institute at West Virginia University

NIH National Institutes of Health

NIH National Cancer Institute

NIH National Institute on Aging

Bryostatin-1 Development Pipeline

2022 Recent News

- Synaptogenix Announces Publication of Peer-Reviewed Scientific Manuscript Evidencing Byrostatin-1's Improved Cognition Over Baseline in Advanced Alzheimer's Disease Patients

Synaptic loss is the major pathologic correlate of Alzheimer's disease and other dementias, and has been shown to occur in very early stages of such diseases.[2]

Bryostatin: Promotes Neuronal Health and Synaptic Regeneration

Bryostatin is a molecule that activates protein kinase C (PKC), which plays an important role in learning, memory, and maintaining the health of synapses — the places where neurons (nerve cells) come into contact with, and send signals to, each other.

Key Accomplishments of Clinical Development Plan:

- Bryostatin demonstrated a favorable safety profile across both completed Phase II Pilot Alzheimer's disease trials
- Current trial has reported no safety issues to date
- Drug has been safely administered in over 1,600 patients
- Cognitive improvement over baseline, not just a slowing of the rate of decline
- Effect is persistent at least one month after dosing

Leadership

Alan Tuchman, M.D., Chief Executive Officer
Clinical Professor of Neurology at New York Medical College, in private practice of neurology in Manhattan; former chief medical officer of Oncolytic Biotech Inc.

Daniel Alkon, M.D., President and Chief Scientific Officer
30 years directing programs on the molecular and structural basis of associative memory at the National Neurologic Institute of NIH; founding scientific director of the Blanchette Rockefeller Neuroscience Institute.

Robert Weinstein, Chief Financial Officer
30 years, as an investment banker, healthcare private equity fund principal, chief financial officer, and public accountant.

Joshua Silverman, Chairman
Co–founder and managing member of Parkfield Funding LLC; former principal and managing partner of Iroquois Capital Management.

Market Snapshot

Share Price	52-Wk. Range	Avg. Vol.	Shares O/S	Market Cap
$8.65 (1/18/22)	$4.40 - $14.50	100K	6.67M	$57.7M

Synaptogenix, Inc. | 1185 Avenue of the Americas, 3rd Floor New York, NY 10036 | www.synaptogen.com
Investor Relations Contact | 800-811-5591 | ir@synaptogen.com

[1] *Fortune Business Insights*
[2] Scheff SW, Price DA. Alzheimer's disease-related alterations in synaptic density: neocortex and hippocampus. J Alzheimers Dis. 2006;9 (3 Suppl): 101-15.
Price and volume quotes from Yahoo! Finance